CapVest Partners completed the acquisition of Stada Arzneimittel AG for €5.2 billion enterprise value on September 2nd, marking Europe's largest leveraged buyout year-to-date and the firm's most significant transaction in its 28-year history. The London-based mid-market specialist purchased the German generics and over-the-counter pharmaceutical business from Bain Capital and Cinven, who acquired Stada in 2017 for €4.3 billion. The deal closed without the participation of Blackstone, KKR, or any bulge-bracket private equity house.

Stada generated €3.6 billion in revenue across 2024 with EBITDA margins near 18%, operating in 50 markets with concentration in Central and Eastern Europe. CapVest structured the transaction with €2.9 billion in senior debt arranged by Deutsche Bank, Goldman Sachs, and UBS, alongside €1.1 billion in subordinated notes and €1.2 billion in equity commitments from its Fund VII vehicle and three European family offices. The leverage multiple sits at 5.8x trailing EBITDA, elevated but within range for defensive healthcare assets with recurring revenue models. The sellers achieved a 2.7x gross multiple over their eight-year hold period, returning approximately €6.1 billion to limited partners before fees.

The transaction signals two structural shifts allocators are tracking. First, European mid-market firms are accessing financing previously reserved for megafund sponsors, reflecting both credit market normalization and bank appetite for non-cyclical healthcare paper. CapVest's ability to arrange €4 billion in debt commitments within 47 days indicates covenant-light structures have migrated fully into the middle market. Second, pharmaceutical carve-outs and secondary buyouts are replacing primary processes as the dominant deal type in European healthcare PE, with four of the six largest European LBOs year-to-date involving sponsor-to-sponsor transfers. This compresses hold periods and raises questions about operational alpha versus financial engineering in return generation.

CapVest plans to expand Stada's biosimilar pipeline and pursue bolt-on acquisitions in the €50-200 million range across Poland, Romania, and the Czech Republic, where the company holds 12-18% market share in generic pharmaceuticals. The firm has allocated €400 million for M&A within the first 24 months post-close and retained Stada's existing management team under revised incentive structures tied to EBITDA growth and free cash flow conversion. The business generates €520 million in annual free cash flow, providing debt service coverage of 1.8x against the senior facility.

Operators should monitor three follow-on events. CapVest will likely launch a dividend recapitalization within 18-24 months if EBITDA expands above €720 million, testing both credit markets and the firm's willingness to lever further. Stada's biosimilar portfolio includes five candidates in Phase III trials with potential approval dates in late 2026 and early 2027, which will determine whether the asset trades at a strategic premium in a subsequent exit. And European antitrust regulators have opened a preliminary review of the transaction's impact on generic drug pricing in seven Eastern European markets, with findings expected by November 2025.

The deal establishes CapVest as a credible acquirer for €3-7 billion pharmaceutical assets that fall between mega-cap PE appetites and traditional mid-market constraints, a category that now includes at least eleven other European healthcare companies trading in sponsor-owned portfolios.